Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases
- PMID: 39475079
- PMCID: PMC11523040
- DOI: 10.1093/ecco-jcc/jjae067
Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases
Abstract
There are growing numbers of older people with inflammatory bowel diseases [IBD]. These older patients are more likely to have other comorbidities and polypharmacy, which can make recognizing and treating IBD complex. Frailty is a newer concept in the IBD field, and we are beginning to recognize the importance of this as a marker of biological age and its association with risk of adverse IBD-related outcomes. In this review article we aim to provide practical insight into the specific challenges facing older patients and their clinicians at each stage of the patient journey. We also discuss the latest understanding of the impact of frailty for these patients with IBD and highlight areas for future research.
Keywords: Ageing; IBD; frailty.
© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Conflict of interest statement
IC has received speaker honoraria from Celltrion, research grants from Celltrion, and a travel grant from Galapagos. CPS has received unrestricted research grants from Warner Chilcott, Janssen, and AbbVie, has provided consultancy to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Galapagos, Ferring, RedX, Arena, and Janssen, and had speaker arrangements with Warner Chilcott, Dr Falk, AbbVie, MSD, Pfizer, Celltrion, and Takeda. SS has received consulting fees from Celltrion, Lilly, Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, and Tillots Pharma, has received payment or honoraria for lectures from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, Janssen, Merck, Warner Chilcott, and Falk Pharma Janssen, and holds research grants from Abbvie, Janssen, Takeda, and Olympus. OT reports no conflicts of interest.
Similar articles
-
Frailty: An Underappreciated Risk Factor for IBD Complications.Curr Gastroenterol Rep. 2024 Dec;26(12):315-322. doi: 10.1007/s11894-024-00945-5. Epub 2024 Sep 5. Curr Gastroenterol Rep. 2024. PMID: 39235680 Review.
-
Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study.BMC Gastroenterol. 2022 Nov 26;22(1):487. doi: 10.1186/s12876-022-02578-2. BMC Gastroenterol. 2022. PMID: 36435785 Free PMC article.
-
Challenges in the management of older patients with inflammatory rheumatic diseases.Nat Rev Rheumatol. 2022 Jun;18(6):326-334. doi: 10.1038/s41584-022-00768-6. Epub 2022 Mar 21. Nat Rev Rheumatol. 2022. PMID: 35314796 Review.
-
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.Clin Gastroenterol Hepatol. 2022 Oct;20(10):2358-2365.e11. doi: 10.1016/j.cgh.2022.01.001. Epub 2022 Jan 6. Clin Gastroenterol Hepatol. 2022. PMID: 34999206 Free PMC article.
-
Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Diseases.Aliment Pharmacol Ther. 2025 Jan;61(2):246-257. doi: 10.1111/apt.18390. Epub 2024 Nov 11. Aliment Pharmacol Ther. 2025. PMID: 39524008
Cited by
-
IBD Across the Ages-A Journey Together.J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii1-ii2. doi: 10.1093/ecco-jcc/jjae118. J Crohns Colitis. 2024. PMID: 39475078 Free PMC article. No abstract available.
References
-
- Coward S, Clement F, Benchimol EI, et al.. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019;156:1345–53.e4. - PubMed
-
- Gisbert JP, Chaparro M.. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459–77. - PubMed
-
- Sturm A, Maaser C, Mendall M, et al.. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis 2017;11:263–73. - PubMed
-
- United Nations. World Population Ageing 2019. New York: Department of Economic and Social Affairs; 2020.
-
- Whitty C. Chief Medical Officer’s Annual Report 2023: Health in an Ageing Society. 2023. https://assets.publishing.service.gov.uk/media/65562ff2d03a8d000d07faa6/....
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources